MYOF and colorectal carcinoma: Further cycloheximide (CHX) chase assays demonstrated that apatinib significantly enhanced MYOF protein degradation, and the proteasome inhibitor MG-132 markedly altered MYOF expression levels in apatinib-treated CRC cells, suggesting that MYOF protein may be degraded through the ubiquitin–proteasome system (Figure 4D,E).